Cardiometabolic Drugs Market

Cardiometabolic Drugs Market Outlook

The global cardiometabolic drugs market size reached US$ 50 Bn in 2021. The sales of cardiometabolic drugs are estimated to surpass a valuation of US$ 70 Bn by 2032, rising at a CAGR of 4% to 5% during the forecast period 2022-2032. Driven by the rising emphasis on the development of novel drugs that offers better results with minimal side effects, the demand for cardiometabolic drugs is projected to top US$ 55 Bn by 2022.

Cardiometabolic drugs are therapeutics medications purposefully used for a vast composition of metabolic disorders and dysfunction including cardiovascular diseases, obesity, diabetes, hypertension, dyslipidemia, central adiposity, and others.

What are the Prominent Factors Augmenting the Demand for Cardiometabolic Drugs in the Market

Due to increasing fast-paced lifestyles, changing eating habits, and rising stress levels, a substantial rise in the burden of lifestyle diseases such as diabetes, obesity, hypertension, and others is being witnessed, creating demand for treatment drugs.

For instance, according to the International Diabetic Foundation, nearly 537 million adults between the age of 20 to 79 are living with diabetes across the world and the number is estimated to reach 643 million by 2030. As cardiometabolic disorders are extensively used by diabetic patients for diverse applications, such as insulin resistance, growing diabetic population is projected to create high remunerative opportunities in the global market.

Which are Key Challenges Restraining the Growth in the Global Cardiometabolic Drugs Market

There are number of side effects associated with the consumption of cardiometabolic drugs such as antidiabetics, anticoagulants, hypertension, dyslipidemia drug, and others such as dyspepsia, vomiting, nausea, prolonged nosebleeds, passing of blood in urine, and others. Hence, rising awareness regarding such severe adverse effects on health is hindering the sales of cardiometabolic drugs in the market.

Why is North America Garnering Maximum Sales of Cardiometabolic Drugs in the Global Market

As per Future Market Insights, North America is forecast to account for the lion’s share in the global cardiometabolic drugs market between 2022 and 2032.

Cardiometabolic disorders and conditions involve a group of abnormalities that are interrelated, leading to a diverse constellation of cardiometabolic drugs used for each indication to limit the disease effect.

The prevalence of cardiovascular diseases is rising at a rapid pace across North America, due to the increasing pollution, smoking, opioid use, and others. According to the Centers for Disease Control and Prevention, nearly 18.2 million adults or around 6.7% of the population across the U.S. have coronary heart disease.

As cardiometabolic drugs play a crucial role in limiting the effect of these diseases along with their treatments, increasing burden of cardiovascular diseases is estimated to bolster the sales in the North America market.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How is South Asia Contributing to the Growth in the Global Cardiometabolic Drugs Market

FMI reveals that South Asia is anticipated to emerge as a highly lucrative market for cardiometabolic drugs during the forecast period 2022-2032.

With growing trend of personalized medication and rising demand for more effective drugs with minimal to no side effects, key manufacturers are focusing on research and development activities for the development of novel drugs.

For instance, in 2020, Natco Pharma, an Indian multinational pharmaceutical company announced launching a novel anti-blood clot medication, Rivaroxaban, under the brand name Xarelto. A multiplicity of such new product launches are expected to favor the demand for cardiometabolic drugs in the South Asia market.

Market Competition

Some of the leading players in the cardiometabolic drugs market are AbbVie Inc,, Besins Healthcare SA., Natco Pharma, Gilead Sciences Inc, Sanofi, InovoBiologic Inc, Carmel Biosciences Inc, Genfit SA, Kochi Prefecture, Cardax Pharmaceuticals, Inc., Abeille Pharmaceuticals, Inc., and others.

Attributed to the presence of such high number of participants and increasing emphasis on the development and launch of for novel drugs, the market is highly competitive.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Sign-Up

Report Scope

Key Segments Profiled in the Cardiometabolic Drugs Market Survey

By Drug Class:

• Weight Loss Drugs
• Antidiabetics Drugs
• Anticoagulants Drugs
• Antiplatelet Drugs
• Impaired Glucose Tolerance Drugs
• Insulin Resistance Drugs
• Hypertension Drugs
• Dyslipidemia Drugs
• Others

By Indication Type:

• Congestive Heart Failure
• Hypertension
• Diabetes
• Obesity
• Others

By Distribution Channel:

• Institutional Sales
• Hospitals
• Clinics
• Retail Sales
• Retail Pharmacies
• E- Commerce/Mail Order Pharmacies
• Others

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa